Current therapeutic options and treatments in development for the management of primary open-angle glaucoma

Jeffrey M. Liebmann, Jeannie K. Lee

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Primary open angle glaucoma (POAG) is the most common type of glaucoma, and is responsible for approximately 90% of glaucoma cases in North America. POAG is characterized by an asymptomatic onset, where patients do not present with symptoms until significant visual loss occurs in late stages of the disease. Importantly, while glaucoma is associated with several risk factors that contribute to damage and disease progression, intraocular pressure (IOP) is the only proven modifiable risk factor at this time. Treatments for POAG include use of pharmacologic and surgical interventions. As of this writing, available pharmacologic options reduce IOP through reduction of aqueous humor production or by facilitating aqueous humor drainage through the uveoscleral outflow pathway (the unconventional pathway). Although cholinergic agonists (eg, pilocarpine) indirectly targets aqueous humor draining through the trabecular meshwork/Schlemm's canal (the conventional outflow pathway), cholinergic agonists are not frequently used, and as of this writing, no agents are currently available that target both the conventional and unconventional outflow pathways. Therapies in late-stage development include trabodenoson, netardsudil, and latanoprostene bunod.

Original languageEnglish (US)
Pages (from-to)S279-S292
JournalThe American journal of managed care
Volume23
Issue number15
StatePublished - Sep 1 2017

Fingerprint

Aqueous Humor
Glaucoma
Cholinergic Agonists
Intraocular Pressure
Trabecular Meshwork
Pilocarpine
North America
Disease Progression
Drainage
Therapeutics
Primary Open Angle Glaucoma

ASJC Scopus subject areas

  • Health Policy

Cite this

Current therapeutic options and treatments in development for the management of primary open-angle glaucoma. / Liebmann, Jeffrey M.; Lee, Jeannie K.

In: The American journal of managed care, Vol. 23, No. 15, 01.09.2017, p. S279-S292.

Research output: Contribution to journalArticle

@article{a3355c636e1b4480b8033ae6f970df2a,
title = "Current therapeutic options and treatments in development for the management of primary open-angle glaucoma",
abstract = "Primary open angle glaucoma (POAG) is the most common type of glaucoma, and is responsible for approximately 90{\%} of glaucoma cases in North America. POAG is characterized by an asymptomatic onset, where patients do not present with symptoms until significant visual loss occurs in late stages of the disease. Importantly, while glaucoma is associated with several risk factors that contribute to damage and disease progression, intraocular pressure (IOP) is the only proven modifiable risk factor at this time. Treatments for POAG include use of pharmacologic and surgical interventions. As of this writing, available pharmacologic options reduce IOP through reduction of aqueous humor production or by facilitating aqueous humor drainage through the uveoscleral outflow pathway (the unconventional pathway). Although cholinergic agonists (eg, pilocarpine) indirectly targets aqueous humor draining through the trabecular meshwork/Schlemm's canal (the conventional outflow pathway), cholinergic agonists are not frequently used, and as of this writing, no agents are currently available that target both the conventional and unconventional outflow pathways. Therapies in late-stage development include trabodenoson, netardsudil, and latanoprostene bunod.",
author = "Liebmann, {Jeffrey M.} and Lee, {Jeannie K.}",
year = "2017",
month = "9",
day = "1",
language = "English (US)",
volume = "23",
pages = "S279--S292",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "15",

}

TY - JOUR

T1 - Current therapeutic options and treatments in development for the management of primary open-angle glaucoma

AU - Liebmann, Jeffrey M.

AU - Lee, Jeannie K.

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Primary open angle glaucoma (POAG) is the most common type of glaucoma, and is responsible for approximately 90% of glaucoma cases in North America. POAG is characterized by an asymptomatic onset, where patients do not present with symptoms until significant visual loss occurs in late stages of the disease. Importantly, while glaucoma is associated with several risk factors that contribute to damage and disease progression, intraocular pressure (IOP) is the only proven modifiable risk factor at this time. Treatments for POAG include use of pharmacologic and surgical interventions. As of this writing, available pharmacologic options reduce IOP through reduction of aqueous humor production or by facilitating aqueous humor drainage through the uveoscleral outflow pathway (the unconventional pathway). Although cholinergic agonists (eg, pilocarpine) indirectly targets aqueous humor draining through the trabecular meshwork/Schlemm's canal (the conventional outflow pathway), cholinergic agonists are not frequently used, and as of this writing, no agents are currently available that target both the conventional and unconventional outflow pathways. Therapies in late-stage development include trabodenoson, netardsudil, and latanoprostene bunod.

AB - Primary open angle glaucoma (POAG) is the most common type of glaucoma, and is responsible for approximately 90% of glaucoma cases in North America. POAG is characterized by an asymptomatic onset, where patients do not present with symptoms until significant visual loss occurs in late stages of the disease. Importantly, while glaucoma is associated with several risk factors that contribute to damage and disease progression, intraocular pressure (IOP) is the only proven modifiable risk factor at this time. Treatments for POAG include use of pharmacologic and surgical interventions. As of this writing, available pharmacologic options reduce IOP through reduction of aqueous humor production or by facilitating aqueous humor drainage through the uveoscleral outflow pathway (the unconventional pathway). Although cholinergic agonists (eg, pilocarpine) indirectly targets aqueous humor draining through the trabecular meshwork/Schlemm's canal (the conventional outflow pathway), cholinergic agonists are not frequently used, and as of this writing, no agents are currently available that target both the conventional and unconventional outflow pathways. Therapies in late-stage development include trabodenoson, netardsudil, and latanoprostene bunod.

UR - http://www.scopus.com/inward/record.url?scp=85047396915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047396915&partnerID=8YFLogxK

M3 - Article

C2 - 29164845

AN - SCOPUS:85047396915

VL - 23

SP - S279-S292

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 15

ER -